Brief: Celldex Announces Positive Results From Phase 3 Embarq-Csu1 And Embarq-Csu2 Studies Of Barzolvolimab Which Met Primary And All Key Secondary Endpoints
22/09/2026 11:59
BRIEF-Celldex Announces Positive Results From Phase 3 Embarq-Csu1 And Embarq-Csu2 Studies Of Barzolvolimab Which Met Primary And All Key Secondary Endpoints Sept 22 (Reuters) - Celldex Therapeutics, Inc. CLDX.O:
CELLDEX ANNOUNCES POSITIVE RESULTS FROM PHASE 3 EMBARQ-CSU1 AND EMBARQ-CSU2 STUDIES OF BARZOLVOLIMAB WHICH MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS
CELLDEX THERAPEUTICS, - PHASE 3 TRIALS MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS AT WEEK 12
CELLDEX THERAPEUTICS, - BARZOLVOLIMAB WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE THROUGH 24 WEEKS
CELLDEX THERAPEUTICS, - TREATMENT TO CONTINUE TO 52 WEEKS; BLA SUBMISSION PLANNED FOR 2027
Source text: ID:nGNXbWmLJn
Further company coverage: CLDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials